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The last decade has witnessed an increasing interest for the role played by the peroxisome proliferator-activated receptor-γ (PPAR-
γ) in controlling inﬂammation in peripheral organs as well as in the brain. Activation of PPAR-γ has been shown to control the
response of microglial cells, the main macrophage population found in brain parenchyma, and limit the inﬂammation. The anti-
inﬂammatory capacity of PPAR-γ agonists has led to the hypothesis that PPAR-γ might be targeted to modulate degenerative
brain diseases in which inﬂammation has been increasingly recognized as a signiﬁcant component. Recent experimental evidence
suggests that PPAR-γ agonists could be exploited to treat ocular diseases suchas diabetic retinopathy, age-related macular degener-
ation, autoimmune uveitis, and optic neuritis where inﬂammation has relevant role. Additional PPAR-γ agonist beneﬁcial eﬀects
could involve amelioration of retinal microcirculation and inhibition of neovascularization. However, PPAR-γ activation could, in
some instances, aggravate the ocular pathology, for example, by increasing the synthesis of vascular endothelial growth factor, a
proangiogenic factor that could trigger a vicious circle and further deteriorate retinal perfusion. The development of new in vivo
and in vitro models to study ocular inﬂammation and how to modulate for the eye beneﬁt will be instrumental for the search of
eﬀective therapies.
Copyright © 2008 Fiorella Malchiodi-Albedi et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The peroxisome proliferator-activated receptor-γ (PPAR-γ)
is a ligand-inducible transcription factor that belongs to
a large superfamily comprising the nuclear receptors for
steroids, thyroid hormones, and retinoids. The PPAR-γ and
thetwocloselyrelatedPPAR-αandPPAR-δ (alsoknownasβ,
NUC-1, or FAAR) are activated by naturally occurring fatty
acids and act as sensors that regulate whole body metabolism
in response to the dietary intake by controlling lipid and car-
bohydratemetabolismandlipidstorage[1].AllthreePPARs,
once agonist-activated,form heterodimers with retinoic X
receptors and regulate speciﬁc target gene transcription by
binding to speciﬁc DNA regions (peroxisome proliferator re-
sponse elements, PPREs) or by a mechanism independent of
PPRE binding, termed transrepression, which begins to be
unravelled [2].
Because of their role in the regulation of genes involved
in lipid and carbohydrate metabolism, PPARs deeply aﬀect
lipid homeostasis and insulin sensitivity [3, 4]. The serum
glucose lowering activity of PPAR-γ has lead to the develop-
ment of speciﬁc PPAR-γ agonists for the treatment of type-2
diabetes and the metabolic syndrome [5]. PPAR-γ agonists
such as thiazolidinediones (TZD), including pioglitazone
(Actos) and rosiglitazone (Avandia), increase insulin sensi-
tivity thereby improving glycaemic control, but also modify
lipidemic proﬁle and decrease blood pressure [6–9]. On the
other hand, ﬁbrates, which are PPAR-α agonists, are preva-
lently antilipidemic drugs, and therapeutic beneﬁts of PPAR-
α and PPAR-γ activations, which only are minimally over-
lapping, have generated interest in dual agonists that target
bothreceptors,thusoﬀeringimprovedinsulinsensitivityand
lipidemic control in the same molecule [10, 11]. This would
provide a therapeutic tool against diabetes and the metabolic
syndrome.
The three PPARs share a high homology, but diﬀer for
tissue distribution and ligand speciﬁcity. PPAR-α is mainly
expressed in tissues with high catabolic rates of fatty acids,
such as the liver, muscle, and heart, whereas PPAR-δ shows
a much wider distribution. PPAR-γ is highly expressed in2 PPAR Research
adipose tissue, where it plays a central role in the regula-
tion of adipocyte diﬀerentiation [12], and in cells of the im-
mune system, including lymphocytes and macrophages. In
peripheral monocytes, PPAR-γ expression is induced during
the process of extravasation from blood vessels into the tis-
sues, and in the course of activation by pro-inﬂammatory
stimuli, suggesting that PPAR-γ is important for promoting
monocyte-macrophage diﬀerentiation and activation and,
thus, controlling inﬂammation [13–16]. As for macrophages
of peripheral tissues, PPAR-γ regulates the activation of mi-
croglial cells, the main macrophage population found in
brain parenchyma, and increasing evidence indicates that
PPAR-γ might modulate brain inﬂammation and neurode-
generation [17] and be exploited as valuable therapeutic tar-
getinneurologicaldiseases[18].Indeed,braininﬂammation
isincreasinglyviewedasatargetfortreatingneurologicaldis-
eases, not only in classical infectious and immune-mediate
disorders such as meningitis or multiple sclerosis, but also in
stroke, trauma,andneurodegenerative diseasesthatwerenot
originally considered to be inﬂammatory [19, 20].
In a similar way, inﬂammation could represent an im-
portant target to treat ocular diseases. In the study of oph-
thalmology, the classical subdivision of pathology textbooks
in metabolic, inﬂammatory, hemodynamic, and degenera-
tive disorders appears artiﬁcial and does not reﬂect the com-
plexityofconditions,whereinﬂammation,dysmetabolicand
hemodynamic disorders, and neurodegeneration often con-
spire to the development of diseases. Paradigmatic example
isdiabeticretinopathy(DR),whereametabolicderangement
(hyperglycemia) triggers a pathologic pathway, characterized
initially by inﬂammation (leukostasis, enhanced retinal vas-
cular permeability, Muller cell, and microglial activation),
followed by microvasculature alterations and ischemia (pro-
liferative DR), eventually leading to degeneration of neu-
ral retina and visual loss. To this complexity, a simplicity in
the natural history may correspond and the course of dif-
ferent retinal diseases may at a certain stage converge to-
ward a similar evolution. For example, pathologic neovas-
cularization may be the same and ominous outcome of DR,
age-related macular degeneration (AMD), and autoimmune
uveitis, conditions that are very far from each other from the
point of view of etiology.
In the present article, we will ﬁrst brieﬂy review the
immune cells that participate to the ocular inﬂammation,
mainly microglia, and the role of PPAR-γ in controlling their
functions.Inasecondpart,wewillconsiderthreeconditions,
where inﬂammation has a relevant function, microglia is in-
volved, and the role of PPARs has been taken into considera-
tion: DR, AMD, and optic neuritis (ON).
2. MICROGLIAL CELLS AND OTHER CELL
POPULATIONS OF THE IMMUNE RESPOSE
IN THE EYE.
Glial cells are the primary participants in the formation of
scars in response to retinal or ocular injury and diseases. In
addition, under normal conditions, they carry out a vari-
ety of supportive functions for the neurons with which they
are closely related. Glial cells include astrocytes, oligoden-
drocytes, the retina-speciﬁc Muller-glial cells, and microglia,
which are considered the main immune resident cells.
Retinal microglia, like their counterpart in the brain, be-
longtothemyeloidlineageandtheirmyeloidprogenitorsen-
ter the nervous system primarily during embryonic and fetal
periods of development. During embryogenesis, microglial
precursorsmigratetotheretinabeforeretinalvascularization
and diﬀerentiate into ramiﬁed, quiescent microglia typical
of adult healthy retina. A second population of phagocytes,
which express macrophage markers, invades the retinal later
through the developing vasculature and remains associated
with the blood vessels (see below). In the adult retina, mi-
croglia are distributed through most of the retinal layers, in-
cluding outer plexiform layer, outer nuclear layer, inner plex-
iform layer, ganglion cell layer, and nerve ﬁber layer. Engraft-
ment experiments have shown that they display some prolif-
erative capacity and have a slow turnover in respect of other
macrophage populations [21]. Disturbances in the number
ordistributionofthesecellsdisruptthenormaldevelopment
of the eye and its related structures. Ritter and collaborators
[22] have recently reported that myeloid progenitors migrate
to vascular regions of the retina where they diﬀerentiate into
microglia and facilitate the normalization of the vasculature,
thus underlining a main role of microglial cells in promoting
and maintaining retinal vasculature during development.
Microglia show particular capacity of interaction with
retinal cells, supervising the immune environment (see
[23] and references therein). As for microglia in the brain
parenchyma, retinal microglial cells are immunocompetent
cells,abletoremovethedebriscreatedduringnormaleyede-
velopmentordegenerativeconditionsbyphagocytosisandto
mount an inﬂammatory and immune response against ocu-
lar injury, infection, and disease.
Under normal conditions, microglia are characterized
by a downregulated phenotype when compared to other
macrophage populations of peripheral tissues. The mainte-
nance of microglia in this “inhibited” state is crucial for the
regulation of the immune state of the retina, which has to
maintain tissue homeostasis while preventing the destructive
potential of inﬂammatory and immune response. The com-
plexity of theseveralintraocular structureson whichthecor-
rect vision is dependent renders the eye particularly vulner-
able to the reactions of the immune system against invad-
ing pathogens or ocular injury. To prevent that a defensive
reaction can transform into a threat to vision in itself, the
eye is equipped with several regulatory mechanisms, which
contributetomaketheeyean“immune-privileged”site[24].
As recently described for the brain parenchyma [25], the im-
mune privilege is not an absolute or an immutable state, but
ratheritistheresultoftheactiveinterplayamongspecialized
cellular elements and speciﬁc microenvironment character-
istics, and it can be overcome in several instances. Among
the main features that account for the ocular immune privi-
legeare is the presence of blood-ocular barriers (the blood-
aqueous barrier and the blood-retinal barrier), which are
physical barriers between the local blood vessels and most
parts of the eye itself, and the peculiar characteristics of the
resident immune cells, namely, microglia, which are largely
dependent on the presence of immunomodulatory factorsFiorella Malchiodi-Albedi et al. 3
Table 1: Retinal pathologies characterized by microglial activation.
Pathology References
Diabetic retinopathy [26–29]
Glaucomatous optic nerve degeneration [30–33]
Human retinitis pigmentosa [34]
Age-related macular degeneration [34, 35]
Retinal ischemia and reperfusion injury [36, 37]
Retinal degeneration [14, 20, 38]
in the aqueous humor and on the cross-talk between mi-
croglia and retinal cells. Several “ligand-receptor-” type in-
teractions between retinal cells and microglia contribute to
maintaining microglia in a nonactivated state. Among these,
theglycoproteinCD200,whichintheretinaisextensivelyex-
pressed in neurons and endothelial cells, and the cognate lig-
and CD200L on microglia [39], and the neuronal chemokine
fractalkine (or CX3CL1) and its microglial receptor CX3CR1
[40].
In spite of their apparent “dormant” state, resting mi-
croglia actively monitor the surrounding microenvironment
with extremely motile processes and protrusions, entering in
contact with other cellular elements and sensing alterations
in the nearby environment, to which they rapidly react. Mi-
croglial activation comprises morphological changes, such
as cellular hypertrophy, retraction of processes, and expres-
sionofsurfacemarkers,aswellasfunctionalchanges,includ-
ingproliferation,migration,phagocytosis,andproductionof
bioactivemolecules.Activatedmicrogliahavebeendescribed
in several forms of retinal injury or disease (see Table 1),
in which they are believed to play major roles, either pro-
t e c t i v eo rd e t r i m e n t a l .I n d e e d ,a c t i v a t e dm i c r o g l i ac a n ,o n
one side, remove the degenerating neurons and contribute
to re-establish tissue integrity; on the other side, they can
secrete proinﬂammatory cytokines such interleukin (IL)-1β,
IL-3, IL-6, tumour necrosis factor (TNF)-α, and interferon
(IFN)-γ, which can be toxic to neurons and photoreceptors
[41, 42] or to other cellular targets such as oligodendro-
cytes [43, 44]. In addition, several of these microglial prod-
ucts can up-regulate the expression of vascular cell adhesion
molecules and chemokines [45–47], thus promoting the re-
cruitment of lymphocytes and macrophages, and enhancing
the immune-mediated tissue damage [23, 48]. In this con-
text, molecules that can enable the control of microglial acti-
vation represent valuable tools to counteract the detrimental
eﬀects of inﬂammation and immune response while foster-
ing those necessary for healing.
Inadditiontomicroglia,othercelltypescontributetothe
immune response in the eye. The perivascular macrophages
reside outside the blood-ocular barrier, in the space that sep-
arates the endothelium of the retinal capillaries and reti-
nal pigment epithelium (RPE). Because of their anatom-
ical location, they escape the tight control to which reti-
nal microglia are subjected and their morphology and im-
munophenotype are very similar to those of macrophages
of peripheral tissues. In close proximity, but separate from
perivascular macrophages are the pericytes, which are be-
lieved to be essential as structural support in microcircula-
tion. In addition, together with astrocytes and Muller glia,
they are considered to play a major role in maintaining the
inner blood-retinal barrier [49]. These cells, of mesodermal
origin, are enclosed within the basal lamina on the ablumi-
nal surface of endothelial cells and contain contractile pro-
teins. Pericytes have been shown to control vessel constric-
t i o na n dr e t i n a lb l o o dﬂ o w[ 50], and are involved in sev-
eral pathological conditions, including hypoxia, hyperten-
sion, and DR. Their activation, since the very early phases of
disease, is thought contribute to the disruption of the blood-
retinal barrier [51]. Finally, the RPE cells are important in
ocularimmuneresponseandinmaintainingtheeyeimmune
privilege. These cells form a monolayer between the neu-
roretina and the choroids and are the essential component of
the outer blood-retinal barrier. One of the main characteris-
tics of RPEcells is the presence of tight junctions at the apical
side of their lateral membrane, which render the monolayer
impermeable for macromolecules and limit access of blood
components to the retina. In addition to several important
supportive functions, including regulation of transport of
nutrients to the photoreceptors, phagocytosis of damaged or
o l dr o do u t e rs e g m e n t s ,a n dp r o d u c t i o no fg r o w t hf a c t o r s ,
RPE cells contribute to the immune and inﬂammatory re-
sponse of the retina by expressing major histocompatibility
complex (MHC) antigens, adhesion molecules, and a variety
of cytokines, which may either promote or enhance immune
responses or down-regulate them [52].
In addition to the cell types so far described, a novel pop-
ulation of dendritic cells has been recently reported in nor-
mal mouse retina, distinguishable by the cell types by the ex-
tent of speciﬁc surface antigens and anatomical tissue loca-
tion [53].
3. DIABETIC RETINOPATHY
Diabetic retinopathy (DR) is one of the most serious compli-
cations of diabetes and the leading cause of blindness among
working-age adults. DR symptoms are mostly due to the vas-
cularalterationsthataﬀecttheretina.Theearlyeventsarein-
creased blood ﬂow and abnormal vessel permeability, due to
the impairment of blood-retinal barrier. They are caused by
hyperglycemia and the other metabolic consequences of ex-
cessglucosedisposal.Asthediseaseprogresses,retinalvascu-
lopathy develops, showing loss of pericytes, smooth muscle
and endothelial cell death, and microaneurysm formation,
resulting in areas of ischemia in the retina. At this stage, up-
regulation of proangiogenic factors in ischemic retina, such
as vascular endothelial growth factor (VEGF), initiates a vi-
cious circle of neovascularization (proliferative DR), charac-
terized by enhanced vascular leakage and formation of new,
weak, and prone-to-break blood vessels, which further dete-
riorates retinal perfusion, worsens ischemia and eventually
leads to visual loss.
Although the pathogenetic cascade connecting these
events is still unclear, evidence suggesting a role for in-
ﬂammation in DR is accumulating, supporting the involve-
ment of both chemical mediators and inﬂammatory cells
in the pathogenesis of the disease [54]. Elevated levels of4 PPAR Research
proinﬂammatory cytokines, such as IL-1β, IL-6 and IL-8,
and TNF-α and vascular cell adhesion molecule-1, have been
found in the vitreous of patients with proliferative DR [55–
57]. Increased VEGF and IL-6 levels were detected in the
aqueous humor of diabetic patients with macular edema
[58].TNF-αwasfoundin epiretinal membranesofprolifera-
tive DR [59]. Data from experimental models are in line with
theseobservations.Instreptozotocin(STZ)-induceddiabetic
rats,changesinretinalbloodvesselpermeability,whichchar-
acterizes the early phases of DR, are paralleled by increase
in the level of the intercellular cell adhesion molecule-1
(ICAM-1),whichfacilitatesthetraﬃckingofleukocytes[60],
and pro-inﬂammatory mediators, such as TNF-α and cyclo-
oxygenase-2 (COX-2) [61, 62].In the same animal model, an
increasedlevelofIL-1β hasbeenobservedandputinrelation
to upregulated inducible nitric oxide synthase (iNOS) [63].
Mice deﬁcient in the leukocyte adhesion molecules CD18
andICAM-1demonstratesigniﬁcantlyfeweradherentleuko-
cytes in the retinal vasculature after induction of diabetes
with STZ [54]. According to some authors, VEGF could be
responsible for the initiation of the inﬂammatory cascade, as
itsadministration invivowasfoundtoinduceretinalICAM-
1 and endothelial NOS (eNOS) expression [64, 65]. As far
as inﬂammatory cells are concerned, microglia seem to be
mostly involved. Microglial activation appears early in the
course of DR, before the onset of overt neuronal cell death
[62]. In STZ-induced diabetic rats, hypertrophic microglia
were observed one month after the onset of diabetes [66],
with signiﬁcant increase also in cell number [67]. In mice
with alloxan-induced diabetes, changes in microglial cell
morphology were the ﬁrst detectable cellular modiﬁcations,
apparently preceding ganglion cell apoptosis and increase in
blood barrier permeability [68]. Treatment of STZ-induced
diabetic rats with minocycline, a semisynthetic tetracycline
that counteracts microglial activation, besides decreasing the
expressionofproinﬂammatorycytokines,decreasedcaspase-
3l e v e l s[ 62], suggesting a potential neuroprotective anti-
apoptotic eﬀect of inhibition of microglial activation.
Considering the role of inﬂammation in the pathogen-
esis of DR, it has been suggested that PPAR-γ ligands ex-
ert therapeutic eﬀects also as modulators of inﬂammation,
besides providing glycemic control [69]. In diabetic pa-
tients, PPAR-γ agonists reduce several markers of inﬂam-
mation, such as serum levels of C-reactive protein, IL-6,
monocyte chemoattractant protein-1 (MCP-1), plasmino-
gen activator inhibitor-1, soluble CD40 ligand, and matrix
metalloproteinase-9 [70–75]. In addition, they have been
shown to induce the suppression of activated NFκBa n dd e -
crease ROS generation in blood mononuclear cells [70, 73].
Modulation of the inﬂammatory process has also been
studied in DR in in vivo models. In streptozotocin-induced
DR, rosiglitazone was shown to inhibit both retinal leukosta-
sis and retinal leakage [76]. The eﬀect was not accompanied
by downregulation of proinﬂammatory cytokines, such as
TNF-α, although the adhesion molecule ICAM was found
reduced. Nitric Oxide (NO) of endothelial origin regulates
ocular blood ﬂow. In the endothelial dysfunction, which
characterizes the early stages of DR, a reduction in the
bioavailability of NO may contribute to impairment of oc-
ular hemodynamics [77]. In bovine aortic endothelial cells,
troglitazone increased NO production in a dose- and time-
dependent manner with no modiﬁcations in eNOS expres-
sion [78]. A study focused on NO production in pericytes
showedthatPPAR-γ isconstitutivelyexpressedinretinalper-
icytes and that troglitazone increases NO production and
iNOS expression in a PPAR-γ-dependent manner, an eﬀect
which is opposite to what observed in cultured microglia
[79, 80]. This study suggests that PPAR-γ agonists, in ad-
dition to improving insulin sensitivity, might also improve
retinal microcirculation in early DR [81]. However, NO is
ad o u b l e - e d g e ds w o r d .O v e r p r o d u c t i o no fN Ob yn e u r o n a l
NOS is supposed to contribute to retinal injury in ischemia
[82, 83]. Thus, although in DR early phase an increase in NO
may contribute to the improvement of retinal microcircu-
lation, in proliferative DR a beneﬁcial eﬀect is doubtful. A
further reason of concern is represented by TZD eﬀects on
VEGF. Several in vivo and in vitro studies have reported in-
creased expression of VEGF in response to PPAR-γ ligands.
TZDs have been found to upregulate VEGF in human vascu-
lar muscle cells [84], in 3T3-L1 adipocytes [85], in cultured
cardiacmyoﬁbroblasts[86].Inbovineaorticendothelialcells
treated with troglitazone, NO increase was accompanied by
upregulation of VEGF and its receptor, KDR/Flk-1 [78]. Ad-
ministration of pioglitazone [87] and troglitazone [85] also
signiﬁcantly increased plasma VEGF levels in diabetic pa-
tients. Considering the role played by VEGF in the develop-
ment and progression of DR, caution has been suggested in
the use of PPAR-γ ligands in patients with advanced disease
[85, 87]. However, in partial disagreement with the results
above reported, antiangiogenic properties of PPAR agonists
havebeen shownboth inin vitroandin vivomodels [35,88–
90]. In neonatal mice, where ischemia was used as a model of
retinal neovascularization, intravitreous injection of rosigli-
tazone or troglitazone inhibited development of new retinal
vessels [91]. In the same study, TZDs have been found to
inhibit retinal endothelial cell proliferation, migration, and
tube formation in response to VEGF treatment [91]. Further
studies are therefore required to clarify the issue.
4. AGE-RELATED MACULAR DEGENERATION
Age-related macular degeneration (AMD) is the leading
cause of vision loss in the elderly in the western world. It
is characterized by degeneration of the macula, the central
areaoftheretinawiththehighestconcentrationofconepho-
toreceptors, responsible for visual acuity and color vision.
Histopathologically, the early phase of AMD is characterized
by formation of drusen, deposits of lipid and cellular de-
bris that are found between the RPE cells and Bruch’s mem-
brane, possibly as a result of RPE degeneration or, as recently
proposed [92], microglial inﬁltration and transformation in
foam cells. As the disease proceeds, photoreceptor degener-
ation and, in the most aggressive cases, choroidal neovascu-
larization(CNV)intervene,withgrowthofnewbloodvessels
from the choroids into the subretinal space. Two major clin-
ical phenotypes of AMD are recognized: nonexudative (dry
type), and exudative (wet type). The latter more frequently
develops into CNV.Fiorella Malchiodi-Albedi et al. 5
AMD is a complex, multifactorial disease and both ge-
netic and environmental factors may contribute at some
level. In the pathogenesis of the disease, both altered angio-
genesis and inﬂammation play a role. The study of patho-
logic angiogenesis in the retina has focused on two main fac-
tors: the angiogenic VEGF [93, 94] and the antiangiogenic
PEDF [94–96], although a number of other factors are im-
plicated(for a review, see [97]). It is widely agreed that in
CNV an imbalance between angiogenic and anti-angiogenic
factors takes place, but what disrupts this delicate equilib-
riumisstillunclear.Severallinesofevidencepointtoinﬂam-
mation as a pathogenetic mechanism. Many risk factors for
AMD are related to inﬂammation, including environmen-
tal factors, such as smoking and low intake of omega-3 fatty
acid [98, 99], and genetic factors, such as polymorphisms of
complementfactorH[100–102]andthechemokinereceptor
CX3CR, which is expressed by microglia and mediates mi-
gration and adhesion in response to its ligand fractalkine or
CX3CL1 [103]. Increased serum levels of IL-6 and C-reactive
protein have been found to be related with progression of
AMD [104]. More recently, IL-6 receptor neutralization has
shown to lead to decrease in the expression of inﬂamma-
tory mediators, such as the chemokine MCP-1, the adhesion
molecule ICAM-1, and VEGF, and to reduce macrophage in-
ﬁltration into CNV in in vivo model of the disease [105].
Inﬂammatory mediators, such as macrophage chemoattrac-
tants and activated complement components, especially C3a
and C5a, are also found in drusen samples from AMD pa-
tients [106–108]. A role for complement in the development
of the disease has been suggested [34]. In line with this hy-
pothesis, it has been observed that genetic ablation of recep-
tors for C3a or C5a reduced VEGF expression, leukocyte re-
cruitment, and CNV [109].
Activation of microglia and inﬁltration of macrophages
have been reported in the human AMD as well as in
experimental CNV [110–112]. In transgenic mice lack-
ing CX3CR1, microglia migrate defectively and accumu-
late in the subretinal space, evoking morphological and
pathological features similar to those observed in human
AMD. In addition, laser-induced CNV was exacerbated in
these mice [92]. A controversy exists regarding the ori-
gin of activated retinal mononuclear phagocytes, that is,
whether they are resident microglia [113, 114] or blood-
d e r i v e db o n em a r r o wm a c r o p h a g e s[ 46, 115]. In support
of the latter hypothesis, it should be noted that systemic
depletion of macrophages using clodronate-ﬁlled liposomes
blocked neovascularization [116, 117]. However, the role
of macrophages is still debated, since some studies suggest
an antiangiogenic role for macrophages. For example, mice
lacking CC chemokine ligand 2 (CCL2) or its receptor, both
involved in chemoattraction of macrophages and/or mi-
croglia, show drusen-like deposits and CNV, suggesting that
macrophage recruitment may protect against AMD [118].
In addition, mice lacking IL-10, an anti-inﬂammatory cy-
tokine known to control macrophage/microglia functions,
had signiﬁcantly reduced neovascularization and increased
macrophage inﬁltrates compared to wild type, in a laser-
induced model of CNV. In these experiments, prevention of
macrophage entry into the eye promoted neovascularization
while direct injection of macrophages signiﬁcantly inhibited
CNV.
As mentioned earlier, beside mononuclear phagocytic
cells, RPE cells have also a role in the inﬂammatory and an-
giogenetic process, as a major source of VEGF and PEDF. In
addition,thereisacross-talkbetweenRPEandmacrophages.
It has been shown that macrophages in CNV are im-
munopositive for VEGF, TNF-α,a n dI L - 1 β [119]. The lat-
ter factors can induce the secretion of IL-8 and MCP-1 in
RPE cells in vitro [120, 121]. MCP-1 is, in turn, involved in
the recruitment of macrophages [122], thus closing the cir-
cle. Indeed, in surgically excised CNV specimens, RPE was
found to express VEGF and MCP-1 and macrophages were
immunolabeled for VEGF [123].
The interest in the role of PPARs in AMD has been
mainly focused on their activities as modulators of angio-
genesis.PPARagonistshaveshownantiangiogenicproperties
both in in vitro and in vivo models [35, 88, 89]. It has been
shown that choroidal ECs and RPE cells express PPAR-γ and
that PPAR-γ ligands inhibit their response to VEGF, without
apparent toxicity to the adjacent retina, in a laser-induced
model of CNV [90]. Decrease in angiogenesis apparently
takes place by inhibition of VEGF, since PPAR-α agonists
are found to inhibit endothelial VEGFR2 expression [124].
An opposite role has been recently described for PPARδ,
which induced endothelial proliferation and angiogenesis in
vitro, through a VEGF-dependent mechanism [125]. The
natural ligand 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)
was found to protect a human RPE cell line from oxidative
stressbyelevatingGSHandenhancingMAPKactivation,but
such activity was independent of its PPAR-γ binding activity
[126]. The roles of inﬁltrating macrophages and/or resident
microglia in the pathogenesis of AMD open the possibility
that PPAR-γ agonists may ameliorate the course of the dis-
ease also through the down-regulation of several proinﬂam-
matory functions of these cells [8] and reference therein, in-
cluding TNF-α and iNOS, and MHC-II expression.
However, possible beneﬁcial eﬀects of PPAR-γ agonists
in the treatment of ocular inﬂammation and, particularly,
of AMD need to be further veriﬁed. It is important to keep
in mind that PPAR-γ is involved in the diﬀerentiation of
macrophagestofoamingcellsandPPAR-γligandscaninduce
expression of adipocyte lipid binding protein (ALBP/aP2),
a gene that is highly expressed in vivo in macrophage/foam
cells of human atherosclerotic plaques [127]. Moreover, ac-
tivation of PPAR-γ has been shown to reduce CCR2 expres-
sioninmonocytesandtheirchemotaxisinresponsetoMCP-
1[ 128]. These PPAR-γ mediated activities are of particular
interest in the view of the recent ﬁnding by Combadi` ere et al.
[92], suggesting that subretinal microglial foam cells might
be the origin of drusen-like deposits and that accumulation
of microglia in the subretinal space may be a driving force in
the pathogenesis of AMD.
5. OPTIC NEURITIS AND RELATED DISORDERS
Optic neuritis (ON), an inﬂammatory, demyelinating dis-
ease of the optic nerve, may be the initial symptom of mul-
tiple sclerosis (MS) or appear in the course of the disease.6 PPAR Research
Table 2: PPAR agonists and EAE.
Agonists Biological activity Receptor References
Troglitazone Amelioration of clinical symptoms. Reduced expression
of proinﬂammatory cytokines, IL1β and TNF-α
PPAR-γ [129]
Ciglitazone, 15d-PGJ2
Decrease of severity and duration of clinical paralysis.
Decrease of CNS inﬂammation and demyelination. De-
crease of IL-12 production
PPAR-γ [130]
15d-PGJ2
Delayintheonsetanddecreaseintheseverityofdisease.
Reduction of Con A- and MBP Ac1–11-reactive, IFN-α-
and IL-4-secreting cells
PPAR-γ [131]
Pioglitazone Decreased mRNA levels of iNOS and the chemokines
MIP1 and RANTES in the central nervous system
PPAR-γ [132]
Gemﬁbrozil and fenoﬁbrate
Dose-dependent suppression of lymphocyte prolifera-
tion. Promotion of IL-4 production and inhibition of
IFN-γ production
PPAR-α [133]
GW0742 Improvement of clinical recovery. Reduction of glial
activation
PPAR-δ [134]
Ciglitazone, 15d-PGJ2
Ameliorationofclinicalandpathologicalsymptoms.In-
hibition of neural antigen-speciﬁc T cell proliferation
PPAR-γ [135]
Gemﬁbroil
Reduction of incidence and clinical signs. Inhibition of
the inﬁltration of inﬂammatory cells into the CNS. Re-
duced expression of proinﬂammatory molecules such as
iNOS, IL-1, IL-6, and TNF-α
no PPAR-γ [136]
Pioglitazone
Prevention of relapse episodes and reduction of mean
clinical scores during the treatment period. Decrease of
IFN-γ levels
PPAR-γ [137]
In any event, nearly half of MS patients develop ON during
the course of the disease. An idiopathic demyelinating dis-
order of the optic nerve also occurs as NeuroMyelitis Optica
(NMO) or Devic’s disease, which is characterized by the co-
existence of usually bilateral and severe optic neuritis with
spinal cord involvement and the presence of a highly spe-
ciﬁc serum autoantibody marker (NMO-IgG), recognizing
the transmembrane channel Aquaporin 4 [138, 139]. The
boundaries between NMO and MS are, however, rather im-
precise, from both the clinical and pathologic points of view
and it is still a matter of controversy whether NMO should
be considered a variant of MS or a separate entity [139, 140].
Consideringtheirroleininﬂammation,thepossiblether-
apeutic eﬃcacy of PPAR-γ agonists has been studied in ex-
perimental autoimmune encephalomyelitis (EAE), an ani-
mal model of the disease where the autoimmune reaction
against myelin is induced in animals by active sensitization
with myelin components. Although several criticisms have
been moved towards this model, EAE still provides a valu-
able tool for improving our understanding on the pathogen-
esis and treatment of MS. EAE is also considered a model
relevant to the study of demyelinated diseases of the optic
nerve [141, 142]. An additional animal model is represented
by T cell receptor transgenic mice speciﬁc for myelin oligo-
dendrocyte glycoprotein (MOG). These mice develop iso-
lated optic neuritis either spontaneously or after sensitiza-
tion with suboptimal doses of MOG [143]. Therapeutic eﬃ-
cacy of PPAR-γ ligands has been demonstrated in terms of
suppression or amelioration of clinical symptoms and de-
creaseofinﬂammatorysigns(seeTable2).Althoughtheanti-
inﬂammatory activities of PPAR-γ agonists are complex and
multifaceted, evidence has been provided suggesting a direct
actionofPPAR-γ agonistsonmicroglia/mononuclearphago-
cytic cells. Indeed, taking part in both innate and adaptive
immune responses, microglia and mononuclear phagocytes
are deeply implicated in the complex inﬂammatory cascade
associated with MS. Their role has been recently and ex-
tensively reviewed [144, 145]. The PPAR-γ natural agonist
15d-PGJ2 [146] and the PPAR-α agonist gemﬁbrozil [133]
were found to signiﬁcantly reduce macrophage inﬁltration
in the lesions. A decreased number of IL-1β-positive cells
were found in EAE brain of mice treated with GW0742 and a
PPAR-δ agonist and this observation was considered indica-
tive of a reduction of glial activation [134]. PPAR-γ inhibi-
tion of microglial cell activation is also supported by in vitro
experiments [8, 79, 80, 147–152].
Notwithstanding the amount of data regarding a thera-
peutic activity of PPAR agonists in EAE, clinical studies are
lacking and report on their clinical use in MS or ON is still
anecdotical [153]. Clinical trials are however in course with
pioglitazone and rosiglitazone.
6. CONCLUSIONS
The promising results obtained in experimental models of
ocular diseases and the recent advancements in the knowl-
edge of the pathogenic mechanisms driving ocular damage
and vision loss strongly point to PPAR-γ as a valuable tar-
get to control inﬂammation and treat invalidating diseases
such as DR, AMD, and ON. Given the complexity of theFiorella Malchiodi-Albedi et al. 7
phenomena that can be inﬂuenced by PPAR-γ activation, in-
volving not only inﬂammation but also retinal microcircu-
lation, neovascularization, and transformation of activated
microglia in foam cells contributing to drusen-like deposits,
further studies are mandatory for a correct evaluation of pro
and cons of using PPAR-γ agonists in ocular disease treat-
ment. The PPAR-γ agonists could also ﬁnd other important
applications in controlling the adverse eﬀects of inﬂamma-
tion that can put at risk the eye integrity and the correct vi-
sion. As an example, some of the adverse reactions described
after liquid artiﬁcial vitreous replacement use in vitreoreti-
nal surgery are a consequence of inﬂammatory reaction and
activation of mononuclear phagocytic cells [154], suggesting
that the use of PPAR-γ agonists could be very advantageous
in controlling the inﬂammatory response to biomaterials.
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